To get better insight into a potential link between the RAF/MAPK pathway inhibition and FGF1 expression in a larger set of melanoma cell lines, we treated M14, UACC-62, and A375 cell lines as well as four additional melanoma cell lines for 24 h with vemurafenib (0.5 μM) or the MEK inhibitors PD184352 (2 μM) and trametinib (50 nM), respectively (Fig. 3d). Here, FGF1 is linked to melanoma.